US Corporate Distress Financial Stress SEC Filings — March 23, 2026

23-03-2026

RenovoRx announced an oversubscribed $10M at-market private placement of ~10.6M common shares at $0.938/share (insiders at $1.029/share) plus milestone warrants for ~5.3M shares, anchored by life science institutional investors and participated in by senior management and board members. Proceeds will accelerate RenovoCath commercialization, which generated $900k in revenue over the first nine months of 2025 from initial purchase orders including repeat and new NCI-designated centers, and advance the Phase III TIGeR-PaC trial to full enrollment by mid-2026 with data in 2027. The financing supports goals of increasing revenue, reducing cash burn, and achieving cash-flow breakeven, with warrants tied to a $1.5M quarterly revenue milestone.

• ·Private placement priced at $0.938 per share for investors ($1.029 for executives/board); warrant exercise at $1.751 ($1.933 for executives/board), exercisable immediately, expire 30 days after $1.5M quarterly revenue announcement or March 30, 2029
• ·Expected closing March 20, 2026, subject to customary conditions
• ·First commercial RenovoCath purchase orders received December 2024
• ·RenovoCath has FDA clearance and Orphan Drug Designation (via IAG) for pancreatic and bile duct cancer

23-03-2026

Nortech Systems Incorporated entered into a new Credit and Security Agreement with Associated Bank, National Association on March 20, 2026, establishing a revolving credit facility of up to $15M (with $1.5M letter of credit sublimit) and a $2.2M term loan, replacing the prior facility set to mature in August 2026. The new facility and term loan mature in March 2029, bear interest at base rate or Term SOFR plus 2.00% (revolver) or 2.25% (term loan), and are secured by substantially all U.S. assets. It includes standard covenants such as a minimum Fixed Charge Coverage Ratio of 1.10:1.00 and typical events of default.

• ·Existing credit facility scheduled to mature in August 2026
• ·New facility secured by substantially all U.S. assets
• ·Financial covenant: Fixed Charge Coverage Ratio of at least 1.10 to 1.00 (EBITDA adjusted less unfunded capex over fixed charges)

23-03-2026

PMGC Holdings Inc. (ELAB) entered into Amendment No. 5 on March 17, 2026, to its consulting agreement with GB Capital Ltd (wholly owned by CEO/CFO/Director Graydon Bensler), setting the annual consultant fee at $300,000 effective January 1, 2026. The company also entered into a similar Amendment No. 5 with Northstrive Companies Inc. (wholly owned by Chairman Braeden Lichti), setting the annual fee at $360,000 effective the same date. These amendments restate fee provisions of prior agreements originally dated October 25, 2024, with no other changes.

• ·Original consulting agreements dated October 25, 2024
• ·Prior amendments dated April 3, 2025; August 12, 2025; October 16, 2025
• ·Filing date: March 23, 2026

23-03-2026

On March 17, 2026, Volato Group, Inc. received a notice from NYSE American LLC indicating non-compliance with continued listing standards under Sections 1003(a)(i) and 1003(a)(ii) of the Company Guide due to stockholders’ equity below $2.0M (for losses in two of three recent fiscal years) and $4.0M (for losses in three of four recent fiscal years). The Company must submit a compliance plan by April 16, 2026, to regain standards by December 17, 2026, or face delisting proceedings, though there is no immediate impact on trading of its Class A Common Stock (SOAR) on NYSE American. Warrants (SOARW) trade on OTC Markets Group, Inc.

• ·Company address: 1954 Airport Road, Suite 124, Chamblee, GA 30341
• ·Telephone: 844-399-8998
• ·SEC Commission File Number: 001-41104
• ·IRS Employer Identification No.: 86-2707040
• ·Emerging growth company status: Yes

23-03-2026

AMERICAN REBEL HOLDINGS INC (formerly CUBESCAPE INC) filed an 8-K on March 23, 2026, covering Items 3.03 (material modifications to rights of security holders), 5.03 (charter or bylaws amendments), 7.01 (Regulation FD disclosure), and 9.01 (financial statements and exhibits). The filing is categorized under Charter/Bylaws Amendments as a material event, with no quantitative financial data, period-over-period comparisons, improvements, declines, or flat performance disclosed in the provided metadata. No additional positive or negative metrics are available.

• ·Company CIK: 0001648087
• ·SIC: 3490 - MISCELLANEOUS FABRICATED METAL PRODUCTS
• ·State of Incorporation: NV; Location: TN; Fiscal Year End: December 31
• ·Mailing/Business Address: 218 3RD AVENUE NORTH, #400, NASHVILLE TN 37201
• ·Phone: 833-267-3235

23-03-2026

Ormat Technologies, Inc. announced a proposed private offering of $600M aggregate principal amount of Series A Convertible Senior Notes due 2031 and $150M of Series B Convertible Senior Notes due 2031, with options for initial purchasers to buy up to an additional $90M Series A and $22.5M Series B. Net proceeds, along with $25M cash on hand, will fund repurchase of a portion of its outstanding 2.50% convertible senior notes due 2027 via private negotiations, up to $25M in common stock repurchases to offset dilution, and general corporate purposes. The notes are unsecured senior obligations with semiannual interest payments starting September 15, 2026, maturing March 15, 2031.

• ·Series B Notes optional repurchase date: March 15, 2027 at 100% principal plus accrued interest.
• ·Notes redeemable at company's option on or after March 20, 2029, if stock price >=130% of conversion price for specified period.
• ·Conversion prior to November 15, 2030 under certain circumstances; cash, shares, or combination for excess over principal.
• ·Offerings to qualified institutional buyers under Rule 144A; unregistered under Securities Act.

23-03-2026

1606 Corp. amended and restated a promissory note to its former CEO Gregory Lambrecht, increasing the principal from $1.22M (issued Nov 1, 2024) to $1.89M effective Dec 31, 2025, due to additional loans provided by him. The note matures Dec 31, 2025 and is convertible at the holder's option into common stock at a 25% discount to the closing bid price, subject to a 9.99% beneficial ownership limit, creating a direct financial obligation with potential shareholder dilution.

• ·Board of directors approved the issuance on March 17, 2026.
• ·Filed as Exhibit 4.1: Amended and Restated Promissory Note dated December 31, 2025.

23-03-2026

Fathom Holdings Inc. and its subsidiaries (E4:9 Holdings LLC, IntelliAgent LLC, Fathom Realty Holdings LLC, and Verus Holdings Inc.) entered into a Security Agreement dated March 18, 2026, with Bed Bath & Beyond, Inc., granting a continuing security interest in their collateral to secure a subordinated secured promissory note with an initial principal of $2M. The agreement includes covenants on collateral maintenance, no dispositions without consent, and remedies upon default. No financial performance metrics or period-over-period comparisons are disclosed.

• ·Agreement filed as EX-10.1 with SEC 8-K on March 23, 2026, covering Items 1.01, 2.03, 9.01.
• ·Debtors' chief executive office and collateral location: 2000 Regency Parkway Drive, Suite 300, Cary, NC 27518.
• ·Requires 10 days' prior written notice for changes in name, location, or mergers.

23-03-2026

Dollar Tree, Inc. entered into a new Credit Agreement dated March 19, 2026, for a term loan facility with lenders listed on Schedule I, Bank of America, N.A. as Agent, and BofA Securities, Inc. as Sole Lead Arranger and Sole Bookrunner. The agreement outlines term loan commitments with borrowing minimums of $1M and multiples starting at $250k, variable Applicable Margins starting at 0% for Base Rate Loans and 1% for Term SOFR Rate Loans (adjustable based on leverage ratio or public debt rating), and a Base Rate floor of 1%. No specific total commitment amount or prior facility details are provided for comparison, resulting in no observable changes.

• ·Leverage Ratio pricing tiers: Level I ≤1.5 to 1.0; Level II ≤2.0 to 1.0; Level III ≤2.5 to 1.0; Level IV ≤3.0 to 1.0; Level V >3.0 to 1.0.
• ·Applicable Margin for Base Rate Loans ranges from 0.000% (Levels I-III) to 0.375% (Level V).
• ·Agreement includes standard covenants, events of default, and representations typical for term loan facilities.

23-03-2026

Janus Living, Inc. entered into the Amended and Restated Operating Agreement for its operating partnership, Janus Living OP, LLC, effective March 17, 2026, governing membership interests, capital contributions, distributions, management, allocations, transfers, and LTIP units. The LLC was originally formed on December 22, 2025, by Healthpeak OP, LLC, with amendments on January 22, 2026, for a name change and on January 23, 2026, for transfer of ownership interest to Janus Living, Inc. No financial metrics, performance changes, or quantitative impacts are disclosed in the agreement.

• ·Original formation date: December 22, 2025
• ·Prior amendments: January 22, 2026 (name change); January 23, 2026 (ownership transfer)
• ·Agreement includes provisions for LTIP Units, equity incentive plans, and REIT compliance (e.g., Adjustment Factor tied to Class A-1 REIT Shares)

23-03-2026

VRM MSP Recovery Partners, LLC, managed by Virage Capital Management LP, provided a one-time $75,000 advance to MSP Recovery, LLC to support its accounts payables, conditional on immediate reimbursement from future loan proceeds (excluding short-term financing from Hazel Partners Holdings, LLC) and agreement to appoint Nader Tavakoli as Chief Restructuring Officer. This follows multiple prior consents allowing MSP Recovery to use recovery proceeds otherwise distributable to the Company. The agreement highlights ongoing liquidity pressures at MSP Recovery, with references to potential debtor-in-possession financing under Chapter 11.

• ·Prior consents via email/letters dated September 5, 2025; October 16, 2025; November 14, 2025; November 26, 2025; December 19, 2025; February 19, 2026
• ·LLC Agreement amendments: August 1, 2020; December 1, 2020; March 9, 2022; July 28, 2023; November 13, 2023

23-03-2026

General Motors Company and General Motors Financial Company, Inc. entered into the Eighth Amended and Restated 364-Day Revolving Credit Agreement dated March 23, 2026, amending and restating the prior Seventh Amended and Restated agreement from March 25, 2025. The facility involves multiple lenders, with JPMorgan Chase Bank, N.A. as Administrative Agent and Citibank, N.A. as Syndication Agent, along with various joint lead arrangers and bookrunners. No specific commitment amounts, pricing grids, or changes in terms are detailed in the filing excerpt.

• ·Filing Type: 8-K, Items: 1.01, 2.03, 9.01
• ·Previous credit agreement effective date: March 25, 2025
• ·Schedules include Commitments (1.1A), Applicable Pricing Grid (1.1C), but details redacted or not provided

23-03-2026

Unusual Machines, Inc. entered into a Placement Agency Agreement on March 19, 2026, with Dominari Securities LLC and JonesTrading Institutional Services LLC for a confidentially marketed public offering of 8,823,529 shares of common stock at $17.00 per share, generating gross proceeds of approximately $150 million before fees and expenses. The offering closed on March 23, 2026, with net proceeds allocated to acquiring additional inventory, general corporate purposes, and working capital. No comparative period data or negative performance metrics were reported.

• ·Placement Agents: Dominari Securities LLC and JonesTrading Institutional Services LLC
• ·Offering pursuant to effective shelf registration on Form S-3 (No. 333-286413), declared effective April 21, 2025
• ·Preliminary prospectus supplement filed March 19, 2026; final prospectus supplement filed March 23, 2026

23-03-2026

General Motors Company and General Motors Financial Company, Inc. entered into the Eighth Amended and Restated 364-Day Revolving Credit Agreement dated March 23, 2026, amending and restating the prior Seventh Amended and Restated agreement from March 25, 2025. The facility involves multiple lenders led by JPMorgan Chase Bank, N.A. as Administrative Agent and Citibank, N.A. as Syndication Agent, with terms including commitments detailed in Schedule 1.1A (not specified in excerpt) and standard covenants such as minimum liquidity and indebtedness restrictions. No quantitative changes or performance metrics are disclosed in the filing.

• ·Agreement replaces Seventh Amended and Restated 364-Day Revolving Credit Agreement dated March 25, 2025.
• ·References related facilities: Sixth Amended and Restated Three Year Revolving Credit Agreement and Fifth Amended and Restated Five Year Revolving Credit Agreement, both dated March 25, 2025.
• ·Covenants include Minimum Liquidity (Section 7.1), Indebtedness limits (Section 7.2), and Asset Sale Restrictions (Section 7.3).

23-03-2026

Everest Group, Ltd. (NYSE: EG) announced a definitive agreement to sell its Canadian Retail Insurance operations, Everest Insurance Company of Canada, to The Wawanesa Mutual Insurance Company, marking a key step in its strategic repositioning and exit from Commercial Retail Insurance operations following the 2025 sale of renewal rights to AIG. The transaction is expected to deliver compelling value to shareholders and transition employees to Wawanesa, with closure anticipated in the second half of 2026 subject to regulatory approvals. No financial terms of the deal were disclosed.

• ·Transaction advisors: Ardea Partners LP (exclusive financial advisor to Everest), Debevoise & Plimpton LLP and Stikeman Elliott LLP (legal advisors to Everest); TD Securities (exclusive financial advisor to Wawanesa), Torys LLP (legal advisor to Wawanesa)
• ·Everest common stock (NYSE: EG) is a component of the S&P 500 index

23-03-2026

Arbor Realty Trust, Inc. (NYSE: ABR) closed a $762.6M commercial real estate mortgage loan securitization, issuing approximately $674.0M in investment grade-rated notes while retaining $88.6M in subordinate interests. The collateral includes $100M capacity for additional loans over up to 180 days, with Notes carrying a weighted average spread of 1.73% over Term SOFR and a reinvestment period of about 2.5 years. Proceeds will repay credit facility borrowings, cover transaction expenses, and fund future loans and investments.

• ·Reinvestment period of approximately two years and six months for principal proceeds.
• ·Notes issued via private placement under an indenture, secured by real estate assets primarily first mortgage bridge loans.
• ·Certain Notes rated by Fitch Ratings, Inc.; all except most subordinate class rated by Kroll Bond Rating Agency, LLC.
• ·Arbor expects to account for the securitization as a balance sheet financing.

23-03-2026

Sonoco Products Company entered into a $300M Term Credit Agreement on March 23, 2026, with Wells Fargo Bank, National Association as Administrative Agent and Wells Fargo Securities, LLC as lead arranger, providing aggregate commitments of $300M for loans to the borrower. Interest rates for Term SOFR/Daily Simple SOFR Loans range from 0.850% (Pricing Level I) to 1.100% (Pricing Level III) based on S&P/Moody's debt ratings, with a ticking fee of 0.125% per annum initially, increasing to 0.250% after 91 days. No performance declines or flat metrics are mentioned in the agreement.

• ·Audited Financial Statements reference consolidated balance sheet as of December 31, 2025.
• ·Base Rate floor of 1.00%.
• ·Debt Ratings determine pricing levels: Level I (≥ BBB/Baa2), II (BBB-/Baa3), III (≤ BB+/Ba1).

23-03-2026

Waters Corporation's subsidiary, Augusta SpinCo Corporation, completed a $3.5B public offering of senior notes consisting of $650M 4.321% due 2027, $600M 4.398% due 2029, $750M 4.656% due 2031, $750M 4.945% due 2033, and $750M 5.245% due 2036, fully guaranteed by Waters and certain subsidiaries. The notes were issued under an indenture with covenants limiting liens, sale-leasebacks, and mergers, and include customary redemption and change of control repurchase rights. Net proceeds, along with cash on hand, will repay $3.5B of a delayed draw term loan from February 2026.

• ·Notes redeemable at Issuer's option (except 2027 Notes) at prices per Indenture terms.
• ·Change of control triggering events allow holders to require repurchase at 101% of principal plus accrued interest.
• ·Indenture covenants limit liens, sale-leaseback transactions, and require conditions for mergers.
• ·Underwriting agreement dated March 17, 2026, with listed representatives.

23-03-2026

Healthpeak OP, LLC, a subsidiary of Healthpeak Properties, Inc., entered into Amendment No. 5 to its Term Loan Agreement dated August 22, 2022, effective March 23, 2026, increasing the aggregate principal amount cap for Term A-1, A-2, A-3, A-4 Loans and additional Incremental Term Loans to $2B. The amendment introduces a new Term A-4 Facility with commitments from Term A-4 Lenders, administered by Bank of America, N.A. No declines, flat performance, or adverse financial metrics were reported.

• ·Previous amendments: Consent and Amendment No. 1 (Feb 10, 2023), No. 2 (Mar 1, 2024), No. 3 (Dec 9, 2024), No. 4 (Oct 3, 2025)
• ·Effectiveness subject to conditions including legal opinions, certifications, no Default/Event of Default, KYC compliance, and payment of fees

23-03-2026

On March 23, 2026, Charging Robotics Inc. entered into an Earn-Out Milestone Amendment Agreement with holders of Milestone Warrants originally issued to Xylo Technologies Ltd., extending the deadline for achieving three earn-out milestones from December 31, 2025, to December 31, 2026, amid ongoing security considerations in Israel. The warrants cover an aggregate of 6,150,000 shares, with vesting contingent on all milestones being met by the new deadline and no partial vesting allowed. The amendment also modifies certain milestone terms without other changes to the underlying Securities Exchange Agreement.

• ·Milestones: (a) Inhouse demonstration of wireless charging system for EV in automated parking; (b) Conditional PO for 1st system for automatic car parks; (c) Commercial agreement for pilot with board-approved organization.
• ·Milestone Warrants issued pursuant to Securities Exchange Agreement dated March 28, 2023.
• ·Shares issuable upon exercise not registered under Securities Act, relying on Section 4(a)(2) and/or Rule 506 exemption.

23-03-2026

Empery Digital Inc. announced a $25M registered direct offering of 4.638M shares and warrants at $5.39 per share (103% of NAV), with closing expected on March 24, 2026, and intends to use proceeds plus cash on hand to reduce outstanding debt by $40M via full repayment of $50M Repo Facility and partial use of $100M credit facility with Two Prime. The company has repurchased 22.35M shares under its $200M repurchase program at an average $5.92/share as of March 20, 2026, resulting in 33.71M shares outstanding post-offering and potential warrant exercises. It sold 63 BTC for $4.6M in the week ending March 20 and holds 3,439 BTC.

• ·Warrants exercisable immediately and expire four years from issuance.
• ·No placement agent engaged; no fees paid.
• ·Shelf registration on Form S-3 effective September 19, 2025.

23-03-2026

Concentrix Receivables, Inc. (Borrower) and Concentrix Corporation (Servicer) entered into the Sixth Amendment to the Receivables Financing Agreement on March 20, 2026, amending the original agreement dated October 30, 2020, with key lenders including PNC Bank (Administrative Agent), TD Bank, Wells Fargo, and MUFG Bank. The amendment is subject to conditions precedent such as executed documents, fee letters, certificates, and legal opinions, and reaffirms no Events of Default or Termination Date occurrence. All prior covenants and the Performance Guaranty remain in full force and effect.

• ·Amendment effective upon satisfaction of conditions including Fourth Amended and Restated Fee Letter and updated Secretary’s Certificates.
• ·Governed by laws of the State of New York.

23-03-2026

Guardian Pharmacy Services, Inc. entered into Stock Purchase Agreements on March 18, 2026, to repurchase up to 1,833,344 shares of Class A common stock using proceeds from public offerings, and consummated an underwritten public offering on March 20, 2026, of 6,900,000 shares at $31.00 per share (5,880,000 from selling stockholders and 1,020,000 newly issued by the company, with proceeds used to repurchase and cancel an equivalent number of shares, resulting in no change to outstanding shares). The offering was non-dilutive but led to the loss of controlled company status under NYSE rules, requiring the establishment of an independent Nominating and Governance Committee. Selling stockholders, including Bindley Capital Partners I, LLC and others, are subject to a lock-up until the later of June 30, 2026, or 180 days after the latest underwriting agreement.

• ·Stock Purchase Agreements executed March 18, 2026; Offering consummated March 20, 2026; Filing dated March 23, 2026.
• ·Company qualified as controlled company prior to Offering due to majority voting power held by selling stockholders; now subject to full NYSE governance requirements with transition periods.

23-03-2026

Resolute Holdings Management, Inc. entered into an Incremental Amendment dated March 18, 2026, to its existing Credit Agreement originally dated February 20, 2026, increasing the Revolving Commitments by $10M through Additional Revolving Commitments provided by Increasing Lenders. The amendment requires satisfaction of conditions precedent including certifications of no Defaults, compliance with covenants on a pro forma basis, legal opinions, and a solvency certificate, with no outstanding Revolving Loans affected in type or interest periods. JPMorgan Chase Bank, N.A. acts as Administrative Agent and Increasing Lender, with Bank of America, N.A. as an Amendment Lender.

• ·Amendment filed as 8-K on March 23, 2026, covering Items 1.01, 2.03, 9.01.
• ·Waiver of certain requirements under Section 2.09(g)(ii) and penultimate sentence of Section 2.09(g) by Required Lenders.
• ·Governing law: State of New York; includes jury trial waiver.

23-03-2026

Perrigo Company PLC entered into an Amended and Restated Credit Agreement dated March 20, 2026, with Perrigo Investments, LLC as the initial borrower and other subsidiaries as designated borrowers, establishing a revolving facility (CUSIP: 71429TAG5) and Term B Facility (CUSIP: 71429TAF7) under Deal CUSIP 71429TAA8. JPMorgan Chase Bank, N.A. serves as Administrative Agent and Collateral Agent, with participation from multiple banks including Wells Fargo, BofA Securities, Goldman Sachs, Morgan Stanley, Mizuho, HSBC, ING, and BNP Paribas as arrangers, bookrunners, syndication agents, and documentation agents. No specific facility sizes, rates, or other financial terms were detailed in the provided filing content.

• ·Filing Date: March 23, 2026
• ·Agreement Effective Date: March 20, 2026
• ·SEC Items: 1.01, 2.03, 9.01
• ·Deal CUSIP Number: 71429TAA8

23-03-2026

Sutro Biopharma reported FY2025 revenue of $102.5 million, up 65% YoY from $62.0 million driven by Astellas and Ipsen collaborations, while R&D expenses fell 34% to $166.4 million and total operating expenses declined 13% to $260.9 million including $53.4 million in restructuring costs. Net loss improved to $191.1 million from $227.5 million YoY, but cash position dropped sharply to $141.4 million from $316.9 million, offset by a $110 million equity raise extending runway to at least Q2 2028. Pipeline progressed with STRO-004 Phase 1 dosing completed in three cohorts (data mid-2026), STRO-227 IND targeted for 2026, and Astellas' TROP2 iADC entering clinic.

• ·Restructuring costs: $53.4M in FY2025 (total cash payments estimated $4.1M-$4.3M)
• ·STRO-004 preclinical HNSTD: 50 mg/kg (clinical start: 1 mg/kg)
• ·AACR 2026 presentations scheduled April 17-22 including oral on STRO-004 and ASP2998
• ·Stockholders' equity shifted to deficit of $132.5M as of Dec 31, 2025 from $44.6M surplus

23-03-2026

Crown Holdings, Inc. entered into a Second Amended and Restated Credit Agreement on March 17, 2026, amending and restating the prior agreement from April 7, 2017, providing for a $800M Dollar Revolving Facility, $800M Multicurrency Revolving Facility, $50M Canadian Revolving Facility, $1,175M Term Loan A Facility, and €499.5M Term Euro Facility, all maturing March 17, 2031. The facilities bear interest at SOFR plus 1.25% at closing (adjustable by up to 0.25% based on Total Leverage Ratio) and are secured by equity interests in U.S. and certain non-U.S. subsidiaries, with guarantees from parent guarantors and subsidiaries. Proceeds were used to refinance prior indebtedness, pay transaction costs, and for general corporate purposes; the agreement includes affirmative/negative covenants, a maximum leverage ratio requirement, and standard events of default.

• ·Facilities secured by equity interests in U.S. subsidiaries and certain non-U.S. subsidiaries (with exceptions).
• ·Borrowings guaranteed by Parent Guarantors, Company, and direct/indirect U.S. subsidiaries and certain non-U.S. subsidiaries.
• ·Mandatory prepayments required under certain circumstances.

23-03-2026

Aptose Biosciences Inc. entered into the First Amendment to the Second Amended and Restated Employment Agreement of Dr. William Rice, its Chairman, President, and CEO, effective March 12, 2026. The amendment confirms that no deferred compensation plan was created, no deferred compensation was earned, and no such benefits are owed to Dr. Rice. It also establishes that Dr. Rice is solely responsible for any potential individual taxes, penalties, and interest on benefits paid or payable under the original agreement dated April 29, 2024.

23-03-2026

California Resources Corporation completed an upsized private offering of an additional $350M aggregate principal amount of 7.000% senior unsecured notes due 2034 on March 23, 2026. The net proceeds, along with cash or borrowings, will fund the redemption of $350M of its 8.250% senior unsecured notes due 2029 at 100% plus applicable premium, expected to close on March 24, 2026. This refinancing lowers the interest rate from 8.25% to 7.00% and extends maturity from 2029 to 2034, with the new notes fungible with the existing $400M issuance under the same indenture.

• ·Notes mature on January 15, 2034, with interest accruing from October 8, 2025, payable semi-annually on January 15 and July 15, commencing July 15, 2026.
• ·Original Indenture dated October 8, 2025; First Supplemental Indenture dated January 16, 2026.
• ·Company may redeem notes starting January 15, 2029, or earlier under certain equity proceeds (up to 40%) or with applicable premium; change of control repurchase at 101%.
• ·Notes guaranteed by existing subsidiaries that guarantee revolving credit facility and 2029 Notes.

23-03-2026

NeOnc Technologies Holdings, Inc. entered a third Securities Purchase Agreement on March 20, 2026, to issue and sell up to 545,583 shares of common stock at $7.20 per share and warrants to purchase up to 545,583 shares at $9.00 exercise price, with an initial closing issuing 138,889 shares and warrants for $1M to one investor. This follows prior agreements raising approximately $13.07M through issuances of over 1.8M shares and warrants. Proceeds will be used for working capital; no performance declines or flat metrics reported.

• ·Third Securities Purchase Agreement offering terminates on April 30, 2026.
• ·Company to file resale registration statement no later than 10 days after Form 10-K filing for year ended December 31, 2025.
• ·Securities issued pursuant to Section 4(a)(2) exemption under Securities Act.

23-03-2026

Harmonic Inc. entered into an Asset Purchase Agreement dated March 20, 2026, with Leone Media Inc. to sell its video business assets, including Identified Products and Services, and equity interests in Acquired Subsidiaries (Harmonic International GmbH, Financiere Kepler SAS, and Harmonic Video Networks Ltd.), while assuming certain Assumed Liabilities. The deal follows the exercise of a put option agreement dated December 8, 2025, on March 16, 2026, after works council consultation in France. No purchase price or financial terms are disclosed in the filing.

• ·Balance Sheet Date: September 30, 2025
• ·Business excludes Harmonic's broadband business
• ·Ancillary Agreements include Intellectual Property Assignment, Transition Services Agreement, and Equity Commitment Letter

23-03-2026

Aureus Greenway Holdings Inc. (Nasdaq: AGH) announced a $20M bridge loan to Autonomous Power Corporation (d/b/a Powerus) to provide working capital and support manufacturing for key programs like Guardian-1, FireShield, and SPY ahead of their previously announced business combination. The financing reflects confidence in the deal to create a publicly traded autonomous systems platform, but remains subject to customary closing conditions, regulatory approvals, and risks including potential delays or non-consummation. No financial impacts or period comparisons were disclosed.

• ·AGH currently owns golf course properties including Kissimmee Bay Country Club and Remington Golf Club in Florida.
• ·Post-merger, combined entity expected to operate as Powerus Corporation focused on defense, critical infrastructure, and precision agriculture.

23-03-2026

On March 20, 2026, Liberty Live Holdings, Inc. closed a privately negotiated exchange of approximately $1,116 million aggregate principal amount of its outstanding 2.375% Exchangeable Senior Debentures due 2053 (Old Debentures) for an equal principal amount of newly issued New Debentures, with $34 million of Old Debentures remaining outstanding. The New Debentures, governed by an indenture with U.S. Bank Trust Company, N.A., carry the same 2.375% interest rate, mature on September 30, 2053, and are exchangeable into cash based on Live Nation Entertainment, Inc. common stock value at an initial rate of 9.5320 shares per $1,000 principal (approximately 10.5 million shares total). No changes in principal amount or interest rate were noted, maintaining the company's overall debt profile.

• ·New Debentures interest accrues from December 31, 2025, payable quarterly starting March 31, 2026.
• ·Initial exchange price approximately $104.91 per share of Live Nation common stock.
• ·Company may redeem New Debentures on or after September 30, 2032; holders have put right on September 30, 2032 at 100% of adjusted principal plus accrued interest.

23-03-2026

Tempest Therapeutics, Inc. entered into a securities purchase agreement on March 20, 2026, for a private placement issuing 462,964 shares of common stock or pre-funded warrants for 462,963 shares, each accompanied by Series A and B warrants to purchase up to 925,927 shares, at $2.16 per unit, expected to raise approximately $2.0 million in gross proceeds (with up to $4.0 million potential from warrant exercises). The deal involves two institutional investors and Factor Bioscience Inc. as strategic investor, with closing on or about March 23, 2026, and proceeds for working capital and general corporate purposes. No financial performance metrics or period comparisons are provided in the filing.

• ·Private Placement closing expected on or about March 23, 2026, subject to customary conditions.
• ·Company to seek stockholder approval for warrant exercises within 90 days of March 20, 2026.
• ·Registration statement for resale shares to be filed with SEC within 15 calendar days of March 20, 2026, effective by 45 days (or 75 days if full SEC review).
• ·Series A Warrants: exercisable post-stockholder approval, 5-year term; Series B Warrants: 24-month term; exercise price $2.16/share.
• ·Pre-Funded Warrants exercisable immediately post-closing at $0.001/share.
• ·30-day lock-up on new common stock sales post-Effectiveness Date, with exceptions.
• ·H.C. Wainwright & Co., LLC acting as exclusive placement agent on best efforts basis.

23-03-2026

Tripadvisor, Inc. (NASDAQ: TRIP) entered into a cooperation agreement with Starboard Value LP, under which Dhiren R. Fonseca and Andrew F. Cates were immediately appointed to the Board, expanding it from eight to ten directors. Starboard will recommend two additional directors for election at the 2026 Annual Meeting of Stockholders, and has agreed to standstill, voting, and other customary provisions. Management and Starboard expressed optimism about the collaboration to drive long-term shareholder value.

• ·Filing date: March 23, 2026
• ·Board will remain at ten directors following the 2026 Annual Meeting
• ·Starboard invested based on Tripadvisor's position as a global leader in online travel

23-03-2026

Core Scientific, Inc. (Nasdaq: CORZ) closed an additional $500 million commitment from JPMorgan Chase Bank, N.A., expanding its 364-day credit facility to a total of $1.0 billion, including a prior $500 million from Morgan Stanley. Borrowings under the facility bear interest at SOFR plus 2.50% and will be used for general corporate purposes, including data center asset development to meet strong demand. CEO Adam Sullivan stated the company is well-positioned to execute its strategy.

• ·The credit facility is a 364-day term.
• ·Proceeds to be used for equipment purchases, pre-development costs, real property acquisitions, and additional energy procurement for data centers.
• ·Company operates facilities for high-density colocation and is converting to support AI-related workloads.

23-03-2026

Crypto Co (CRCW) has entered into a Mutual Transfer and Release Agreement effective October 16, 2025, to rescind its prior acquisition of 50.1% of Starchive.io, Inc.'s outstanding capital stock completed via SPA on October 8, 2025, by returning the Purchased Company Shares to sellers, canceling 433,633,691 Buyer shares and convertible Notes originally issued. As part of the agreement, CRCW will issue 151,748,756 new restricted common shares to Starchive.io within 5 business days, subject to Rule 144, lock-up, and a 5% monthly trading volume limit. The parties provide mutual general releases of all claims related to the original transaction, with limited indemnities for regulatory costs.

• ·Agreement signed March 19, 2026; 8-K filed March 23, 2026
• ·No Buyer Shares or Notes transferred/sold prior to rescission
• ·Covered Seller Losses limited to regulatory fees and related attorneys’ fees directly from rescission
• ·New Shares subject to Rule 144 and brokerage statement requests

23-03-2026

Azitra, Inc. announced a private placement financing via a securities purchase agreement with institutional investors including Stonepine Capital and Nantahala Capital, providing initial gross proceeds of $10.5M from 10,470 shares of Series A Preferred Stock and potential additional $20.9M upon cash exercise of warrants, for total gross proceeds up to $31.4M. The funds will support new protein and peptide research programs for the cosmetic and cosmeceutical markets, leveraging their genetic engineering platform amid a biotech cosmetic ingredients market projected to grow from $2.3B in 2024 to $3.7B by 2030. The transaction is expected to close on or about March 20, 2026, subject to customary conditions and stockholder approval.

• ·Closing expected on or about March 20, 2026, subject to customary conditions.
• ·Warrants exercisable post-stockholder approval; Series B Warrants expire 18 months after approval; Series C Warrants expire 30 days after public announcement of human cosmetic study data on filaggrin technology.
• ·Series A Preferred Stock converts automatically to ~8,129 common shares per preferred share post-stockholder approval, subject to beneficial ownership limits.
• ·FDA Fast Track designation received for ATR-04 in EGFRi associated rash; open IND for ATR-04; Phase 1b trial ongoing for ATR-12 in Netherton syndrome.
• ·Company must register resale of common stock issuable upon conversion/exercise.

23-03-2026

Infinity Natural Resources, Inc. (NYSE: INR) announced the pricing of an upsized $550M private placement of 7.625% senior notes due 2031 by its subsidiary Infinity Natural Resources, LLC, increased from the previously announced $500M and priced at par. The notes mature on April 1, 2031, with semi-annual interest payments starting October 1, 2026, and are guaranteed by the Issuer’s subsidiaries that guarantee its revolving credit facility. Net proceeds will repay outstanding borrowings under the revolving credit facility and for general corporate purposes, with closing expected on March 20, 2026.

• ·Notes priced at par
• ·Interest payable semi-annually on April 1 and October 1, commencing October 1, 2026
• ·Offering to qualified institutional buyers under Rule 144A and non-U.S. persons under Regulation S
• ·Operations focused on Utica Shale in eastern Ohio and Marcellus/Utica Shales in southwestern Pennsylvania

23-03-2026

Ondas Holdings Inc. (ONDS) has entered into a definitive agreement to acquire World View Enterprises, a leader in high-altitude balloon ISR and stratospheric remote sensing, building on a prior $10 million strategic investment and partnership. The acquisition aims to create a multi-domain ISR platform integrating stratospheric persistence via World View's Stratollite platform with Ondas' autonomous aerial and ground systems for defense, homeland security, and critical infrastructure. Targeted markets include the Department of War, Department of Homeland Security, allied defense organizations, and critical infrastructure operators.

• ·Filing Date: March 23, 2026
• ·SEC Filing Items: 1.01, 3.02, 7.01, 8.01, 9.01

23-03-2026

Otter Tail Power Company, a subsidiary of Otter Tail Corp (OTTR), entered into a Note Purchase Agreement dated March 19, 2026, authorizing the issuance and sale of $170M in senior unsecured notes, comprising $100M 5.33% Series 2026A Notes due March 19, 2036, and $70M 6.04% Series 2026B Notes due June 4, 2056. The first closing for Series 2026A is scheduled for March 19, 2026, and the second closing for Series 2026B on June 4, 2026, providing the company with additional long-term financing at fixed rates. No performance declines or flat metrics are mentioned in the filing.

• ·Notes sold at 100% of principal amount.
• ·Denominations of at least $100,000.
• ·Legal opinions required from Dorsey & Whitney LLP, General Counsel of the Company, and ArentFox Schiff LLP.

23-03-2026

Strategy Inc's Pricing and Financing Committee authorized an increase in the number of authorized shares of Variable Rate Series A Perpetual Stretch Preferred Stock from 70,435,353 to 282,556,565 shares, representing a more than 300% expansion in authorization. The Certificate of Increase was executed and filed on March 23, 2026, pursuant to Section 151(g) of the Delaware General Corporation Law. No shares were issued in this action; it expands capacity for potential future issuances.

• ·Action taken pursuant to authority from the Board of Directors and Second Restated Certificate of Incorporation.
• ·Filed as Exhibit 3.1 under Items 1.01, 1.02, 5.03, 8.01, 9.01 of 8-K.

23-03-2026

Sterling Real Estate Trust entered into its Sixteenth Amended and Restated Advisory Agreement with Sterling Management, LLC on March 19, 2026, effective April 1, 2026, extending the prior agreement for an additional one-year term with substantially the same terms and conditions. The agreement was adopted by the Company and filed as Exhibit 10.1. No financial terms or changes were detailed beyond the extension.

• ·Agreement filed with SEC on March 23, 2026
• ·Registrant details: North Dakota incorporation, Commission File Number 000-54295, IRS EIN 90-0115411, principal offices at 4340 18th Ave South Ste. 200, Fargo, North Dakota 58103

23-03-2026

Comstock Holding Companies, Inc. (Nasdaq: CHCI) completed the acquisition of The Reed, a 417-unit Class A multifamily property in Rockville, Maryland, on March 23, 2026, through a joint venture with a Benefit Street Partners-advised institutional fund, with Comstock Partners, LC co-investing. The acquisition expands Comstock's Rockville submarket footprint to more than 900 apartment units across three transit-oriented properties, including BLVD Forty Four and BLVD Ansel. CHCI subsidiaries will manage the property, which is adjacent to the Shady Grove Metro Station.

• ·The Reed built in 2015 and financed by NewPoint Real Estate Capital via Freddie Mac.
• ·Comstock founded in 1985.

23-03-2026

ZRCN Inc. and subsidiary Zircon Corporation entered a $12.5M senior secured revolving credit facility with Altriarch Holdings SPV, LLC on March 17, 2026, maturing March 17, 2029, to refinance an existing $15M loan with FGI Worldwide, LLC and provide working capital flexibility, with up to $5M additional commitments possible. The facility carries interest at 3-month SOFR + 8.75%, requires compliance with financial covenants like maximum tangible net worth and minimum fixed charge coverage ratios, and includes prepayment premiums of 1.5%, 1%, and 0.5% in years 1-3. It is secured by substantially all assets excluding IP, with CEO John Stauss as limited guarantor and pledges from the four largest shareholders.

• ·Maturity date extendable by one year at debtor's request.
• ·Interest payments due monthly starting April 14, 2026.
• ·Lender has right of first refusal on future IP-secured debt offers.
• ·Full principal due upon default; ranks senior to other indebtedness.

23-03-2026

Serina Therapeutics secured up to $30M in a private placement of common stock and pre-funded warrants at $2.25 per share (68% premium to March 17, 2026 closing price), with a first tranche of $15M expected to close March 20, 2026, and a second tranche of up to $15M by April 30, 2026; warrants provide 50% coverage at $5 exercise price (273% premium), potentially adding up to $33.3M if exercised, extending runway into 2H 2027. Proceeds will fund the ongoing SER-252 Phase 1b registrational study for advanced Parkinson’s under the 505(b)(2) NDA pathway. Greg Bailey, M.D., was appointed Co-Chairman alongside Simba Gill, Ph.D., leading the financing.

• ·First patient dosed in SER-252 registrational trial; initial dosing in Australia, expanding to U.S.
• ·Blinded safety review of Cohort 1 expected Q3 2026 to advance to Cohort 2.
• ·Topline results from SAD study arm targeted H1 2027.
• ·Existing Senior Unsecured Convertible Promissory Note from September 9, 2025 amended to eliminate additional funding rights.
• ·Warrants have 4-year term, callable after Cohort 2 first dose or September 30, 2026, if share price >$10.